ARTICLE | Finance
Aura finds the right mix
Why VCs thought the time was right to invest in Aura's nanoparticle story
March 16, 2015 7:00 AM UTC
Aura Biosciences Inc. has been developing its viral nanoparticle technology without the backing of institutional investors since 2009. New VC investors told BioCentury that Aura's work over the past 12-24 months to find the right indication and companion drug for the platform were enough to attract their investment.
Aura raised $21 million in a series B round early this month led by new investor Advent Life Sciences. New investors Chiesi Ventures, Ysios Capital and Alexandria Venture Investments also participated, along with existing investors Li-Cor Biosciences and Henri Termeer, former chairman, president and CEO of Genzyme Corp...